Literature DB >> 20886662

Postoperative myocardial injury after major head and neck cancer surgery.

Peter Nagele1, Lesley K Rao, Mrudula Penta, Dorina Kallogjeri, Edward L Spitznagel, Laura F Cavallone, Brian Nussenbaum, Jay F Piccirillo.   

Abstract

BACKGROUND: Patients with head and neck cancer often have multiple risk factors for coronary artery disease. Yet, little is known about the incidence of postoperative myocardial injury after major head and neck cancer surgery and its clinical relevance. The aim of this study was to determine the risk of postoperative myocardial injury in patients undergoing major head and neck cancer surgery.
METHODS: This was a retrospective cohort study of all patients who underwent major head and neck cancer surgery (n = 378) at a single major academic center from April 2003 to July 2008. Peak postoperative troponin I (TnI) concentration was the primary outcome.
RESULTS: Of 378 patients who underwent major head and neck cancer surgery, 57 patients (15%) had development of an elevated TnI; 90% of these occurred within the first 24 hours after surgery. Preexisting renal insufficiency (unadjusted OR [OR]: 4.60; 95% CI 1.53-13.82), coronary artery disease (OR: 2.33; 95% CI 1.21-4.50), peripheral vascular disease (OR: 2.83; 95% CI 1.31-6.14), hypertension (OR: 2.22; 95% CI 1.20-4.12), and previous combined chemotherapy and radiation (OR: 2.68; 95% CI 1.04-6.91) were associated with elevated postoperative TnI levels. Patients with elevated TnI levels had a significantly longer length of stay in the hospital (8.5 vs 10.1 days; p = .014) and ICU (3 vs 4.5 days; p = .001) and an 8-fold increased risk of death at 60 days after surgery (adjusted OR: 8.01, 95% CI 2.03-31.56). At 1 year, patients with an abnormal postoperative TnI level were twice as likely to die (OR 1.93; 95% CI 1.02-3.63).
CONCLUSIONS: Patients who undergo major head and neck cancer surgery are at significant risk for postoperative myocardial injury, which is a strong predictor of 60-day mortality after surgery. Monitoring of myocardial injury during the first postoperative days, as well as optimizing preventive cardiac care, may be helpful to reduce postoperative mortality rates.
Copyright © 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20886662      PMCID: PMC3017648          DOI: 10.1002/hed.21577

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  32 in total

1.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Authors:  Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

Review 2.  5-Fluorouracil cardiotoxicity: a critical review.

Authors:  W J Gradishar; E E Vokes
Journal:  Ann Oncol       Date:  1990-11       Impact factor: 32.976

3.  Cardiac troponin I predicts short-term mortality in vascular surgery patients.

Authors:  Lauren J Kim; Elizabeth A Martinez; Nauder Faraday; Todd Dorman; Lee A Fleisher; Bruce A Perler; G Melville Williams; Daniel Chan; Peter J Pronovost
Journal:  Circulation       Date:  2002-10-29       Impact factor: 29.690

4.  Predictors of perioperative complications in head and neck patients.

Authors:  D Gregory Farwell; Dominic F Reilly; Ernest A Weymuller; Deborah L Greenberg; Thomas O Staiger; Neal A Futran
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-05

5.  Perioperative complications, comorbidities, and survival in oral or oropharyngeal cancer.

Authors:  Karina de Cássia Braga Ribeiro; Luiz Paulo Kowalski; Maria do Rosário Dias de Oliveira Latorre
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2003-02

6.  Cardiac troponin after major vascular surgery: the role of perioperative ischemia, preoperative thallium scanning, and coronary revascularization.

Authors:  Giora Landesberg; Morris Mosseri; Vadim Shatz; Inna Akopnik; Moshe Bocher; Michael Mayer; Haim Anner; Yacov Berlatzky; Charles Weissman
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

7.  Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery.

Authors:  Giora Landesberg; Vadim Shatz; Inna Akopnik; Yehuda G Wolf; Michael Mayer; Yacov Berlatzky; Charles Weissman; Morris Mosseri
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

8.  Performance of a revised cardiac troponin method that minimizes interferences from heterophilic antibodies.

Authors:  Wesley J Kim; Omar F Laterza; Karl G Hock; James F Pierson-Perry; Delores M Kaminski; Martine Mesguich; François Braconnier; Régine Zimmermann; Martina Zaninotto; Mario Plebani; Atef Hanna; George S Cembrowski; Mitchell G Scott
Journal:  Clin Chem       Date:  2002-07       Impact factor: 8.327

Review 9.  Anaesthetic implications of anticancer chemotherapy.

Authors:  S Kvolik; L Glavas-Obrovac; K Sakic; D Margaretic; I Karner
Journal:  Eur J Anaesthesiol       Date:  2003-11       Impact factor: 4.330

10.  Prognostic importance of comorbidity in a hospital-based cancer registry.

Authors:  Jay F Piccirillo; Ryan M Tierney; Irene Costas; Lori Grove; Edward L Spitznagel
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

View more
  2 in total

1.  High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery.

Authors:  Peter Nagele; Frank Brown; Brian F Gage; David W Gibson; J Philip Miller; Allan S Jaffe; Fred S Apple; Mitchell G Scott
Journal:  Am Heart J       Date:  2013-06-24       Impact factor: 4.749

2.  Dose-response effect of postprocedural elevated cardiac troponin level on adverse clinical outcomes following adult noncardiac surgery: a systematic review protocol of prospective studies.

Authors:  Tao An; Yue Tian; Jingfei Guo; Wenying Kang; Tao Tian; Chenghui Zhou
Journal:  BMJ Open       Date:  2021-06-18       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.